Search research articles
Contact Us
Filters
Showing results (71-80 of 100) with videos related to
Page
of 10
Sort By:
Blood
|
February 24, 2007
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
Hagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses
Jorge E Cortes, Hagop M Kantarjian, Stuart L Goldberg, et al.
Blood
|
August 23, 2014
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report
Fabiana Ostronoff, Megan Othus, Robert B Gerbing, et al.
Hematological Oncology
|
June 28, 2020
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
Tariq I Mughal, Naveen Pemmaraju, Bethan Psaila, et al.
Cancer Cell
|
November 19, 2011
Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk
Liang Li, Min Li, Canlan Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase
Timothy Hughes, Giuseppe Saglio, Susan Branford, et al.
The Lancet. Haematology
|
December 22, 2015
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
Giovanni Martinelli, Vivian G Oehler, Cristina Papayannidis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 20, 2010
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies
Nicolaus Kröger, Ulrike Bacher, Peter Bader, et al.
Haematologica
|
July 1, 2024
<i>Erratum</i> to: Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies
David W Woolston, Nathan D Lee, Mazyar Shadman, et al.
Haematologica
|
December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
Deborah L White, Jerald Radich, Simona Soverini, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 100) with videos related to
Sort By:
Page
of 10
Blood
|
February 24, 2007
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
Hagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses
Jorge E Cortes, Hagop M Kantarjian, Stuart L Goldberg, et al.
Blood
|
August 23, 2014
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report
Fabiana Ostronoff, Megan Othus, Robert B Gerbing, et al.
Hematological Oncology
|
June 28, 2020
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
Tariq I Mughal, Naveen Pemmaraju, Bethan Psaila, et al.
Cancer Cell
|
November 19, 2011
Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk
Liang Li, Min Li, Canlan Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase
Timothy Hughes, Giuseppe Saglio, Susan Branford, et al.
The Lancet. Haematology
|
December 22, 2015
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
Giovanni Martinelli, Vivian G Oehler, Cristina Papayannidis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 20, 2010
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies
Nicolaus Kröger, Ulrike Bacher, Peter Bader, et al.
Haematologica
|
July 1, 2024
<i>Erratum</i> to: Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies
David W Woolston, Nathan D Lee, Mazyar Shadman, et al.
Haematologica
|
December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
Deborah L White, Jerald Radich, Simona Soverini, et al.
Page
of 10